爱体育平台(中国)酒曲有限公司(akrevia.com)创办于2001年1月，注册资金6.80 亿元，集团净资产达14.80 亿元，是一家专业生产山东梁山大曲,芝麻香型专用曲的梁山大曲厂家，并提供有关于山东酒曲价格和梁山大曲价格等信息，质量优越，服务上乘。
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $30M
Founded date: 2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.09.2018 | Series A | $30M | F-Prime Ca... |
Mentions in press and media 9
| Date | Title | Description |
| 03.03.2020 | Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing | - |
| 28.09.2018 | Biotech Startup Akrevia Therapeutics Lands $30M to Develop Next-Gen Cancer Immunotherapies | Akrevia Therapeutic, a Cambridge, MA-based biotech startup focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics has raised $30 million in funding led by F-Prime Capital Partners and Atlas Venture. The funding wil... |
| 28.09.2018 | Term Sheet — Friday, September 28 | THREE THINGS Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop DIRTY DEALINGS: I first reported on ‘Uber for trash’ startup Rubicon Global almost exactly one year ago when I reviewed mul... |
| 27.09.2018 | Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture | Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced the closing of a $30 million Series A financing led by F-Prime Capital Partne... |
| 27.09.2018 | Akrevia Therapeutics Scores $30M | CAMBRIDGE, MA, Akrevia Therapeutics today announced the closing of a $30 million Series A financing. >> Click here for more funding data on Akrevia Therapeutics >> To export Akrevia Therapeutics funding data to PDF and Excel... |
| 27.09.2018 | Akrevia launches with $30M in Series A financing | The company’s development platform, Aklusion, is designed to allow antibodies, cytokines and chemokines to be activated only once they have reached the tumor microenvironment. Its lead program is a monoclonal antibody that targets CTLA4, an... |
| 27.09.2018 | Akrevia Therapeutics Raises $30M in Series A Financing | Akrevia Therapeutics, a Cambridge, Mass.-based biopharmaceutical company focused on developing tumor-targeted immuno-oncology therapeutics, closed a $30m Series A financing. The round was led by F-Prime Capital Partners and Atlas Venture. T... |
| 27.09.2018 | Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture | - |
| - | Akrevia launches with $30M in Series A financing | A company developing a preclinical immunotherapy drug has launched with a two industry veterans at the helm and a round of venture capital. Cambridge, Massachusetts-based Akrevia Therapeutics said Thursday that it had closed $30 million in ... |